tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
SUPNINSPRGENAXSMRAREIRTC
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

RGEN quote by TradingView

The following discussion of our business contains forward-looking statements that involve risks and uncertainties. 10-K, Item 1

Employees
2,000
Headquarters
Waltham, MA
CEO
Olivier Loeillot
Next results
around Feb 23, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $738.3M through the costs to a net profit of $48.9M · income statement of the 10-K

7% operating margin
Revenue to Gross profit: $386.2MRevenue to Cost of revenue: $352.0MGross profit to Operating profit: $55.2MGross profit to Operating expenses: $331.1MOperating profit to Net profit: $48.9MOperating profit to Tax & other: $6.3MOperating expenses to R&D: $54.2MOperating expenses to Sales, admin & other: $276.9M Revenue: $738.3M REVENUE $738.3M +16% Y/Y Gross profit: $386.2M · 52% margin GROSS PROFIT $386.2M 52% margin Cost of revenue: $352.0M · 48% of revenue COST OF REVENUE $352.0M 48% of revenue Operating profit: $55.2M · 7% margin OPERATING PROFIT $55.2M 7% margin Operating expenses: $331.1M · 45% of revenue OPERATING EXPENSES $331.1M 45% of revenue Net profit: $48.9M · 7% margin NET PROFIT $48.9M 7% margin Tax & other: $6.3M · 1% of revenue TAX & OTHER $6.3M 1% of revenue R&D: $54.2M · 7% of revenue R&D $54.2M 7% of revenue Sales, admin & other: $276.9M · 38% of revenue SALES, ADMIN & OTHER $276.9M 38% of revenue
Gross profit $386.2M 52% margin
Operating profit $55.2M 7% margin
Net profit $48.9M 7% margin
The full income statement, year by year

RGEN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 16.4%, above 68% of 154 peers (their median 10.4%) REVENUE GROWTH 16.4% · above 68% Gross margin: 53.5%, above 32% of 107 peers (their median 63.8%) GROSS MARGIN 53.5% · above 32% Operating margin: 2.3%, above 33% of 138 peers (their median 10.2%) OPERATING MARGIN 2.3% · above 33% Net margin: -1.5%, above 27% of 153 peers (their median 6.8%) NET MARGIN -1.5% · above 27% FCF margin: 13.2%, above 59% of 144 peers (their median 9.9%) FCF MARGIN 13.2% · above 59% Return on capital: 1.6%, above 6% of 89 peers (their median 9.2%) RETURN ON CAPITAL 1.6% · above 6%
RGEN Peer median Below the median

What changed

28 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 26, 2026 against Mar 14, 2025.

Risk factors
28 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Late filing notice (NT 10-K or NT 10-Q)
NT 10-K filed Mar 3, 2025: the company said its 10-K would be late
10-K · XBRL
Material weakness in internal control
“Based on these unremediated material weaknesses, the Company’s management concluded that at December 31, 2025, the Company’s internal control over financial reporting was not effective.”
10-K · XBRL
Accounting checks
9 other checks clear, 2 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
4 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

2facts worth reading about the other 9 checks found nothing to note

  • Late filing notice (NT 10-K or NT 10-Q)
    NT 10-K filed Mar 3, 2025: the company said its 10-K would be late
  • Material weakness in internal control
    “Based on these unremediated material weaknesses, the Company’s management concluded that at December 31, 2025, the Company’s internal control over financial reporting was not effective.”
  • Receivables +18.2% ($134.1M to $158.6M) vs revenue +16.4% ($634.4M to $738.3M), +1.9 pts apart
8 more checks with nothing to note
  • Cash from operations $117.4M vs net income $48.9M (FY ending Dec 31, 2025)
  • Inventory +19.2% ($143.0M to $170.5M) vs revenue +16.4% ($634.4M to $738.3M), +2.9 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No longer listed: Addressed the. Same as last year: Accounting for acquisition; Matter in Our; Audit
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

28 paragraphs in Risk Factors that were not in the 10-K filed Mar 14, 2025. Quoted as filed.

All 28 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 14, 2025 10-K, ITEM 1A
    Risks Related to Product Development, Strategic Investments, Collaborations and Acquisitions
  2. Item 1A · new paragraph · not in the 10-K filed Mar 14, 2025 10-K, ITEM 1A
    As part of our growth strategy, we may enter into strategic investments, collaborations, joint ventures, and similar arrangements to expand our capabilities, access new technologies and enter new markets. These transactions involve significant risks and uncertainties that could adversely affect our business, financial condition, or…
  3. Item 1A · new paragraph · not in the 10-K filed Mar 14, 2025 10-K, ITEM 1A
    To mitigate these risks, we have implemented strategies to reduce tariff exposure and closely monitor trade policy developments. However, recent litigation challenging the legality of certain tariffs before the U.S. Supreme Court introduces additional uncertainty. If such tariffs are deemed unlawful, resulting policy reversals or…
  4. Item 1A · new paragraph · not in the 10-K filed Mar 14, 2025 10-K, ITEM 1A
    Effective internal controls are necessary to provide reliable financial reports and to assist in the effective prevention of fraud. Any

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$801.5M$632.4M$634.4M$738.3M
Net income$186.0M$35.6M−$25.5M$48.9M
Operating cash flow$172.1M$113.9M$175.4M$117.4M
Free cash flow$87.2M$77.7M$149.7M$93.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$738.3M ▲ 16.4% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

4 filings in the last 30 days · SEC EDGAR

All filings

About the company

Repligen Corp, Waltham, MA · from the 10-K filed Feb 26, 2026

The following discussion of our business contains forward-looking statements that involve risks and uncertainties. When used in this report, the words “intend,” “anticipate,” “believe,” “estimate,” “plan” and “expect” and similar expressions as they relate to us are included to identify forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements and are a result of certain factors, including those set forth under “Risk Factors” and elsewhere in this Annual Report on Form 10-K (“Form 10-K”).

Headquarters
Waltham, MA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 27, 2026
Incorporated in
DE

Employees, at the top of the page: "We have approximately 2,000 employees and operate globally with offices and manufacturing sites located at multiple locations in the United States, Europe and Asia" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Mar 14, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.